OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr El-Jawahri on the Benefits of Earlier Palliative Care in Hematologic Malignancies

September 20th 2024

Areej El-Jawahri, MD, discusses the potential benefits of earlier palliative care for patients with hematologic malignancies.

Dr Srinivas on the Role of Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC

September 19th 2024

Sandy Srinivas, MD, discusses the role of lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer.

Dr Rimm on the Limitations of HER2 IHC Assays in Breast Cancer

September 19th 2024

David Rimm, MD, PhD, discusses the limitations of current HER2 immunohistochemistry assays in breast cancer.

Dr Secord on the Safety of Mirvetuximab in Recurrent Platinum-Sensitive Ovarian Cancer

September 19th 2024

Angeles A. Secord, MD, MHSc, discusses safety findings from the PICCOLO trial of mirvetuximab soravtansine in recurrent, platinum-sensitive ovarian cancer.

Dr Drakaki on Paradigm-Shifting Trials in Non–Clear Cell RCC

September 19th 2024

Alexandra Drakaki, MD, PhD, discusses key trials that have shaped the treatment paradigm in non–clear cell renal cell carcinoma.

Dr Amanam on the Optimal Use of JAK Inhibitors in the Current Myelofibrosis Treatment Paradigm

September 19th 2024

Idoroenyi Amanam, MD, discusses the myelofibrosis treatment paradigm, highlighting patients who may derive the most benefit for JAK inhibitor treatment.

Dr Lonial on the Impact of the CoMMpass Study on Personalized Medicine in Multiple Myeloma

September 18th 2024

Sagar Lonial, MD, FACP, discusses the broad impact of the CoMMpass study on understanding the molecular underpinnings of multiple myeloma.

Dr Gordon on Shifts in the R/R MCL Treatment Paradigm

September 18th 2024

Leo I. Gordon, MD, discusses the evolution of the treatment paradigm in relapsed/refractory mantle cell lymphoma.

Dr Wolf on Unmet Needs With Surgery in Mesothelioma Treatment

September 18th 2024

Andrea Wolf, MD, MPH, discusses challenges in conducting randomized controlled trials to assess the role of surgery in the treatment of mesothelioma.

Dr Morgans on Previously Reported Data From the ARAMIS Trial in nmCRPC

September 18th 2024

Alicia Morgans, MD, MPH, discusses prior data and follow-up analysis of the ARAMIS trial in nonmetastatic castration-resistant prostate cancer.

Dr Drakaki on the Evolution of Non–Clear Cell RCC Subtype Classifications

September 18th 2024

Alexandra Drakaki, MD, PhD, discusses how the classification of subtypes of non–clear cell renal cell carcinoma has evolved in recent years.

Dr Gadgeel on Long-Term Data With Amivantamab/Lazertinib in EGFR+ Advanced NSCLC

September 17th 2024

Shirish M. Gadgeel, MD, discusses long-term follow-up data from the MARIPOSA study for patients with EGFR-positive advanced non–small cell lung cancer.

Dr Seetharamu on Current Platforms Utilized for Molecular Testing in Lung Cancer

September 17th 2024

Nagashree Seetharamu, MD, MBBS, discusses currently utilized platforms and workflows for molecular testing in lung cancer at Northwell Health.

Dr Patel on the Impact of Donor-Engrafted Clonal Hematopoiesis on Outcomes With Auto-/Allo-HSCT

September 17th 2024

Shyam A. Patel, MD, PhD, discusses the impact of donor-engrafted clonal hematopoiesis on the risk of disease relapse and survival outcomes with allo- and auto-HSCT.

Dr Yuan on the Evolution of Radiation Therapy Approaches in Breast Cancer

September 17th 2024

Yuan Yuan, MD, PhD, discusses radiation therapy approaches across various of breast cancer subtypes.

Dr Mehta on FDA-Approved Treatment Options in Later-Line Hematologic Malignancies

September 17th 2024

Amitkumar Mehta, MD, discusses FDA-approved treatment options for patients with diffuse large B-cell lymphoma and follicular lymphoma in later lines.

Dr Ye on the Safety and Efficacy of BL-B01D1 in Locally Advanced/Metastatic Urothelial Carcinoma

September 17th 2024

Dingwei Ye, MD, PhD, discusses the safety and efficacy outcomes of a clinical trial evaluating BL-B01D1 in locally advanced or metastatic urothelial carcinoma.

Dr Andre on the Efficacy of Nivolumab/Ipilimumab in MSI-H/dMMR mCRC Subgroups

September 16th 2024

Thierry Andre, MD, discusses subgroup and safety analyses of the phase 3 CheckMate 8HW trial of frontline nivolumab plus ipilimumab in MSI-H/dMMR mCRC.

Dr Popat on OS Outcomes With Amivantamab Plus Chemotherapy in EGFR-Mutated, Advanced NSCLC

September 16th 2024

Sanjay Popat, BSc, MBBS, FRCP, PhD, discusses OS data with amivantamab plus chemotherapy in EGFR-mutated, advanced NSCLC after progression on osimertinib.

Dr Garcia-Manero on the Association Between Hemoglobin Levels and QOL in Lower-Risk MDS

September 16th 2024

Guillermo Garcia-Manero, MD, discusses the relationship between hemoglobin levels and QOL in patients with lower-risk myelodysplastic syndromes.